The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma

[1]  E. Vittinghoff,et al.  Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. , 1999, The Journal of infectious diseases.

[2]  B. Yip,et al.  The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. Manfredi,et al.  Pulmonary Kaposi's sarcoma in AIDS patients treated with combined chemotherapy and recombinant human granulocyte colony-stimulating factor. , 1998, Journal of chemotherapy.

[4]  A. Tulpule,et al.  Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Goebel,et al.  Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy. , 1998, European journal of medical research.

[6]  M. Zazzi,et al.  Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir. , 1998, AIDS.

[7]  A. Tulpule,et al.  Emerging treatments for epidemic (AIDS‐related) Kaposi's sarcoma , 1998, Current opinion in oncology.

[8]  D. Scadden.  AIDS-related malignancies. , 1998, Current opinion in oncology.

[9]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[10]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Goedert,et al.  Spectrum of AIDS-associated malignant disorders , 1998, The Lancet.

[12]  C. Pellet,et al.  Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV‐related Kaposi's sarcoma , 1998, AIDS.

[13]  D. Aboulafia.  Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. , 1998, Mayo Clinic proceedings.

[14]  J. Sparano,et al.  Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma , 1998, Medical oncology.

[15]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[16]  F. Goebel,et al.  Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. , 1998, European journal of medical research.

[17]  D. Greenblatt,et al.  Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir , 1998, Journal of clinical pharmacology.

[18]  S. Stewart,et al.  Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Reiss,et al.  Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. , 1998, AIDS.

[20]  S. Ebrahim,et al.  Geography of AIDS‐associated Kaposi's sarcoma in Europe , 1997, AIDS.

[21]  C. Pellet,et al.  Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. , 1997, AIDS.

[22]  B. Tan,et al.  The use of new antiretroviral therapy in combination with chemotherapy. , 1997, Current opinion in oncology.

[23]  White Rm.  LIPOSOMAL DAUNORUBICIN IS NOT RECOMMENDED IN PATIENTS WITH LESS THAN ADVANCED HIV-RELATED KAPOSI'S SARCOMA , 1997 .

[24]  M. Conant,et al.  Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. , 1997, AIDS.

[25]  C. Wood,et al.  Activation of HHV-8 by HIV-1 tat , 1997, The Lancet.

[26]  K. Sepkowitz,et al.  Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. , 1997, AIDS.

[27]  J. Sahai.  Risks and synergies from drug interactions. , 1996, AIDS.

[28]  M. Polis,et al.  Drug interactions in patients infected with human immunodeficiency virus. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  J. V. Von Roenn,et al.  Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Andrew Carr,et al.  HIV protease inhibitors , 1996, AIDS.

[31]  A. Tulpule,et al.  Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Raffeld,et al.  Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma , 1994, Nature.

[33]  S. Chevret,et al.  Results of chemotherapy in 30 AIDS patients with symptomatic pulmonary Kaposi's sarcoma. , 1994, Thorax.

[34]  Aquilur Rahman,et al.  Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin. , 1993, AIDS research and human retroviruses.

[35]  S. Krown,et al.  Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Colletti,et al.  Pulmonary Kaposi's sarcoma: clinical findings and results of therapy. , 1989, The American journal of medicine.

[37]  M. Broggini,et al.  Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors. , 1984, Cancer treatment reports.

[38]  F. Muggia,et al.  Kaposi's sarcoma: a new staging classification. , 1983, Cancer treatment reports.

[39]  M Rocchetti,et al.  NL-FIT: a microcomputer program for non-linear fitting. , 1983, Computer programs in biomedicine.

[40]  Y. Barenholz,et al.  Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. , 1982, Cancer research.

[41]  V. Soriano,et al.  Regression of invasive AIDS-related Kaposi's sarcoma following antiretroviral therapy. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  B. Walker,et al.  Report of the NIH Panel To Define Principles of Therapy of HIV Infection* , 1998, Annals of Internal Medicine.

[43]  R. White.  Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma. , 1997, AIDS (London).